"There are a small number of discoveries and inventions that have potential to impact the
course of humanity. Tackling age-related disease is one of these. Vincere’s team brings
decades of experience in biology, technology, and drug discovery to this fight - so we may
all benefit from a brighter tomorrow."
- Spring Behrouz Chief Executive Officer
vìncere /ˈvintʃere/: to win, to conquer
Vincere develops small molecule therapeutics to improve mitochondrial quality.
Natural mechanisms of mitochondrial quality control decline with age, leading to the neurodegeneration seen
in Parkinson's disease which affects 10 million patients worldwide.
Vincere is a recipient of a $1M grant from the Michael J Fox Foundation, a Phase I SBIR grant
from the National Institutes of Health (NIH), and is a resident of the JLABS incubator at LabCentral in Cambridge, MA.
Biology is complex with a rapidly growing body of knowledge. Proprietary simulation and AI from NeuroInitiative enables
our team to move faster and synthesize new discoveries into efficient therapeutic programs.